Skip to main content
Erschienen in: World Journal of Surgery 6/2005

01.06.2005

Preoperative Albendazole and Scolices Viability in Patients with Hepatic Echinococcosis

verfasst von: Carlos Manterola, M.D., Ph.D., Juan A. Mansilla, M.D., Flery Fonseca, M.Sc.

Erschienen in: World Journal of Surgery | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

To determine the plasmatic and intracystal concentrations of albendazole sulfoxide (AS) and correlate them with the viability of the scolices in patients surgically treated for hepatic hydatid cysts (HHC) that received albendazole preoperatively, as an indirect way of evaluating the scolicide efficacy of the drug. A non-consecutive series of patients with uncomplicated HHC, underwent operation at the Department of Surgery, Regional Hospital of Temuco, Chile, between 2001 and 2002. The patients were given 10 mg/kg/day of albendazole for 4 days prior to the surgery. Intraoperative samples of venous blood and hydatid fluid were taken, in which the plasmatic concentration (PIC) and intracystal concentration (ICC) of AS were measured by means of high-performance liquid chromatography. With the remaining hydatid fluid, the viability of the scolices was examined. The following variables were taken into consideration: diameter, type of cyst, number of cysts, and development of cyst–biliary communications. Descriptive statistics were used in the calculation of medians, averages, and standard deviations, and analytical statistics were used for the comparison of continuous variables applying the t-test and the Mann-Whitney U-test. A total of 26 patients with HHC, with a median age of 39.5 years (range: 16–80 years); 16 were women (61.5%). Nineteen patients presented only one cyst (73.1%), and the diametric median of the cysts was 14.5 cm (range: 7–30). Fourteen patients presented univesicular cysts (53.9%), and the remaining 12 had multivesicular cysts (46.1%). The average PIC of AS in the whole series was 1.88 ± 0.5 μg/ml and the ICC was 0.26 ± 0.2 μg/ml. The ICC in viable hydatid cysts was 0.25 μg/ml versus 0.28 μg/ml in non-viable cysts (p = 0.7556). The absence of association between intracystal levels of AS and the viability of the scolices allows one to posit indirectly that albendazole is ineffective as a scolicidal agent administered preoperatively for 4 days.
Literatur
1.
Zurück zum Zitat Sapunar J. Hidatidosis. In Atíias A. Neghme A, editors, Parasitología Clíníca, Mediterráneo, 1984;297–311 Sapunar J. Hidatidosis. In Atíias A. Neghme A, editors, Parasitología Clíníca, Mediterráneo, 1984;297–311
2.
Zurück zum Zitat Apt, W, Pérez, C, Rycke, P. 1996Nonconventional treatment of human hydatidosisRev. Med. Chile12413851389PubMed Apt, W, Pérez, C, Rycke, P. 1996Nonconventional treatment of human hydatidosisRev. Med. Chile12413851389PubMed
3.
Zurück zum Zitat Manterola, C, Acencio, L, Bahamondes, J, et al. 1997Liver hydatidosis. Descriptive study of clinical and therapeutic aspects of a consecutive series of casesRev. Chil. Cir. (Chile)49352359 Manterola, C, Acencio, L, Bahamondes, J,  et al. 1997Liver hydatidosis. Descriptive study of clinical and therapeutic aspects of a consecutive series of casesRev. Chil. Cir. (Chile)49352359
5.
Zurück zum Zitat Busel, D. 1991Hydatidosis epidemiology. determination of high risk groups and the utility of educational interventions as rational alternativeRev. Med. Surg. (Chile)161011 Busel, D. 1991Hydatidosis epidemiology. determination of high risk groups and the utility of educational interventions as rational alternativeRev. Med. Surg. (Chile)161011
6.
Zurück zum Zitat Franchi, C, Di Vico, B, Teggi, A. 1999Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamatesClin. Infect. Dis.29304309CrossRefPubMed Franchi, C, Di Vico, B, Teggi, A. 1999Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamatesClin. Infect. Dis.29304309CrossRefPubMed
7.
Zurück zum Zitat Serra, I, García, V, Pizarro, A, et al. 1999A universal method to correct underreporting of communicable diseasesReal incidence of hydatidosis in Chile 1985–1994. Rev. Med. Chile127485492 Serra, I, García, V, Pizarro, A,  et al. 1999A universal method to correct underreporting of communicable diseasesReal incidence of hydatidosis in Chile 1985–1994. Rev. Med. Chile127485492
8.
Zurück zum Zitat Morris, DL, Chinnery, JB, Georgiou, G, et al. 1987Penetration of albendazole sulphoxide into hydatid cystsGut287580PubMed Morris, DL, Chinnery, JB, Georgiou, G,  et al. 1987Penetration of albendazole sulphoxide into hydatid cystsGut287580PubMed
9.
Zurück zum Zitat Manterola, C, Barroso, M, Vial, M, et al. 2003Liver abscess of hydatid origin: clinical features and results of aggressive treatmentAust. N. Z. J. Surg.73220224CrossRef Manterola, C, Barroso, M, Vial, M,  et al. 2003Liver abscess of hydatid origin: clinical features and results of aggressive treatmentAust. N. Z. J. Surg.73220224CrossRef
10.
Zurück zum Zitat Barriga, O. 1971Survival of Echinococcus granulosus scolices in saline solution and in hydatid fluid at different temperaturesBol. Chil. Parasitol.268084PubMed Barriga, O. 1971Survival of Echinococcus granulosus scolices in saline solution and in hydatid fluid at different temperaturesBol. Chil. Parasitol.268084PubMed
11.
Zurück zum Zitat García Llamazares, JL, Alvarez Felipe, AL, Redondo, PA, et al. 1997Fertility and viability study of ovine hydatid cystsRev. Esp. Salud Publica71445449PubMed García Llamazares, JL, Alvarez Felipe, AL, Redondo, PA,  et al. 1997Fertility and viability study of ovine hydatid cystsRev. Esp. Salud Publica71445449PubMed
12.
Zurück zum Zitat Manterola, C, Oberg, C, Soto, O, et al. 2000Scolex viability of human liver hydatid cystsRev. Chil. Cir. (Chile)52471476 Manterola, C, Oberg, C, Soto, O,  et al. 2000Scolex viability of human liver hydatid cystsRev. Chil. Cir. (Chile)52471476
13.
Zurück zum Zitat Laboratorio Merck. Introduction to HPLC. Practical Applications. Santiago, Chile, Merck, 1990;3–50 Laboratorio Merck. Introduction to HPLC. Practical Applications. Santiago, Chile, Merck, 1990;3–50
14.
Zurück zum Zitat Zeugin, T, Zysset, T, Cotting, J. 1990Therapeutic monitoring of albendazole: a high-performance Liquid chromatography method for determination of its active metabolite albendazole sulfoxideTher. Drug Monit.12187190PubMed Zeugin, T, Zysset, T, Cotting, J. 1990Therapeutic monitoring of albendazole: a high-performance Liquid chromatography method for determination of its active metabolite albendazole sulfoxideTher. Drug Monit.12187190PubMed
15.
Zurück zum Zitat Valois, ME, Takayanagui, OM, Bonato, PS, et al. 1994Determination of albendazole metabolites in plasma by HPLCJ. Anal. Toxicol.188690PubMed Valois, ME, Takayanagui, OM, Bonato, PS,  et al. 1994Determination of albendazole metabolites in plasma by HPLCJ. Anal. Toxicol.188690PubMed
16.
Zurück zum Zitat Morris, D, Dykes, P, Marriner, S, et al. 1985Albendazole: objective evidence of response in human hydatid diseaseJ.A.M.A.25320532057PubMed Morris, D, Dykes, P, Marriner, S,  et al. 1985Albendazole: objective evidence of response in human hydatid diseaseJ.A.M.A.25320532057PubMed
17.
Zurück zum Zitat García, J, Bolás-Fernández, F, Torrado, J. 1999Quantitative determination of albendazole and its main metabolites in plasmaJ. Chromatogr. B Biomed. Sci. Appl.723265271CrossRefPubMed García, J, Bolás-Fernández, F, Torrado, J. 1999Quantitative determination of albendazole and its main metabolites in plasmaJ. Chromatogr. B Biomed. Sci. Appl.723265271CrossRefPubMed
18.
Zurück zum Zitat Morris, DL. 1987Preoperative albendazole therapy for hydatid cystBr. J. Surg.74805806PubMed Morris, DL. 1987Preoperative albendazole therapy for hydatid cystBr. J. Surg.74805806PubMed
19.
Zurück zum Zitat Gil-Grande, LA, Rodríguez-Caabeiro, F, Prieto, JG, et al. 1993Randomized controlled trial of efficacy of albendazole in intra-abdominal hydatid diseaseLancet34212691272CrossRefPubMed Gil-Grande, LA, Rodríguez-Caabeiro, F, Prieto, JG,  et al. 1993Randomized controlled trial of efficacy of albendazole in intra-abdominal hydatid diseaseLancet34212691272CrossRefPubMed
20.
Zurück zum Zitat Aktan, AO, Yalin, R. 1996Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cystEur. J. Gastroenterol. Hepatol.8877879PubMed Aktan, AO, Yalin, R. 1996Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cystEur. J. Gastroenterol. Hepatol.8877879PubMed
Metadaten
Titel
Preoperative Albendazole and Scolices Viability in Patients with Hepatic Echinococcosis
verfasst von
Carlos Manterola, M.D., Ph.D.
Juan A. Mansilla, M.D.
Flery Fonseca, M.Sc.
Publikationsdatum
01.06.2005
Erschienen in
World Journal of Surgery / Ausgabe 6/2005
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-7691-6

Weitere Artikel der Ausgabe 6/2005

World Journal of Surgery 6/2005 Zur Ausgabe

OriginalPaper

Reply

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.